The Intestinal Microbiome in Triple Negative Breast Cancer Treated with Immunotherapy

Part of paid clinical trials in Baton Rouge, Louisiana.

Sponsor
Pennington Biomedical Research Center
Study ID
NCT06318507
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Fecal microbial diversity — COMBINATION_PRODUCT
    Fecal microbiome diversity via 16S rRNA and metagenomic sequencing

Study Details

This study will determine how the intestinal microbiome differs between patients with obesity and early triple-negative breast cancer who achieve a pathologic complete response from preoperative anti-PD-1 immunotherapy (pembrolizumab) versus patients who do not.

Key Dates

Start date
Mar 11, 2024
Status verified
Feb 2025
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
25 participants (estimated)

Primary Outcome Measure

Pathologic Complete Response (pCR) [ Time Frame: Week 24 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Pennington Biomedical Research CenterBaton RougeLouisiana70808
Justin Brown, Ph.D.
[email protected]
225-763-2715

Find similar trials in Baton Rouge, LA

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
Pennington Biomedical Research Center· Baton Rouge, LA

Related Studies